You have pins and needles everywhere, and nobody knows why.

MTHFR encodes an enzyme that’s central to a process called methylation. Think of methylation as your cells’ way of converting raw nutrients into the active forms they can actually use. Your nerves depend heavily on this process. Myelin, the insulation around your nerve fibers, is built from methylated compounds. The neurotransmitters that help your nerves communicate with each other depend on methylation. When methylation is working well, your nerves are protected and your pain signals are modulated properly.

The problem: the MTHFR C677T variant, carried by roughly 40% of the population, reduces this enzyme’s efficiency by 40 to 70%. That means your cells are converting B vitamins into usable forms at a fraction of the rate they should be. You can eat perfectly and still be functionally depleted at the cellular level, leaving your nerves starved of the compounds they need to stay healthy and regulate pain.

What this feels like: pins and needles that don’t respond to oral B vitamins, tingling that seems worse after stress or exercise, brain fog that accompanies the nerve symptoms, and a sense that your body is operating on a fuel reserve.

COMT is an enzyme that breaks down catecholamines, a class of neurotransmitters including dopamine and norepinephrine. These molecules aren’t just about mood and focus. They’re also central to your brain’s natural pain-dampening system. When catecholamines are cleared slowly from your synapses, pain signals linger longer and feel more intense. When they’re cleared quickly, pain passes through your awareness more efficiently.

The variant: the COMT Val158Met slow variant is carried by roughly 25% of the population in homozygous form. People with this variant clear catecholamines more slowly. That means pain signals linger in your nervous system longer than they should, amplifying the sensation of tingling and making your nerves feel hypersensitive to normal touch.

What this feels like: pins and needles that feel electric or exaggerated, tingling that seems to get worse with stress or caffeine, a sense that your nervous system is stuck in an amplified state, and relief when you rest in a quiet, low-stimulation environment.

VDR encodes the vitamin D receptor, a protein that sits on nearly every cell in your body, including neurons. Vitamin D isn’t just about bone health. In your nervous system, it regulates calcium handling in nerve cells, supports myelin production, and modulates immune function to prevent nerve inflammation. Your body can have plenty of vitamin D circulating in the bloodstream, but if your VDR isn’t functioning optimally, your cells can’t actually use it.

The problem: several VDR variants reduce the receptor’s ability to bind vitamin D and translate it into cellular action. The most common is the Taq1 variant, carried by roughly 50% of the population. People with certain VDR variants can have normal or even high vitamin D blood levels but still experience nerve dysfunction because their cells simply cannot access the vitamin D they need.

What this feels like: pins and needles that don’t improve despite supplementing vitamin D, nerve pain that worsens in winter or with limited sun exposure, tingling that accompanies muscle weakness or cramping, and a pattern of never quite feeling the benefit of vitamin D supplementation despite taking it.

SOD2 encodes superoxide dismutase 2, an antioxidant enzyme that works inside your mitochondria, the power plants of your cells. Mitochondria generate energy, but they also produce free radicals as a byproduct. SOD2 neutralizes these radicals before they can damage cell membranes, proteins, or DNA. Your nerve cells have enormous numbers of mitochondria because maintaining a nervous system requires massive amounts of energy. When SOD2 isn’t working optimally, oxidative stress accumulates inside nerve cells, degrading the insulation around nerve fibers and triggering inflammatory pain signals.

The variant: the SOD2 Ala16Val variant, carried by roughly 30% of the population, reduces the enzyme’s ability to transport into the mitochondria and function optimally. People with this variant accumulate oxidative stress inside their nerve cells faster than their body can clean it up, leading to progressive nerve inflammation and pain signaling.

What this feels like: pins and needles that seem to get worse over time, tingling that accompanies fatigue or poor recovery from exercise, nerve pain that improves with rest and worsens with activity, and a sense that your nervous system is struggling under metabolic stress.

OPRM1 encodes the mu-opioid receptor, a protein on nerve cells that responds to your body’s endogenous opioids, natural pain-relief molecules your brain produces continuously. These aren’t pharmaceuticals. They’re your nervous system’s own morphine-like compounds. When an mu-opioid receptor is working normally, it binds these endogenous opioids with high affinity, effectively dampening pain signals. When a receptor is less sensitive, the same amount of endogenous opioid has a weaker effect, and pain signals get through with less dampening.

The variant: the OPRM1 A118G variant, the G allele, is carried by roughly 10 to 15% of the population in European ancestry and 40% in East Asian ancestry. People with the G variant have mu-opioid receptors that are less sensitive to endogenous opioids, meaning their body’s natural pain-relief system is running at reduced capacity, leaving them with a chronically lower pain threshold.

What this feels like: pins and needles that feel more intense than others seem to experience, a need for higher doses of pain medication than would normally be expected, tingling that doesn’t respond well to standard pain management, and a lifelong pattern of feeling pain more acutely than peers.

FAAH encodes fatty acid amide hydrolase, an enzyme that breaks down anandamide, one of your body’s endocannabinoids. Anandamide is your nervous system’s own cannabis, a molecule that binds to cannabinoid receptors throughout your brain and body to reduce pain signaling, calm inflammation, and modulate anxiety. The longer anandamide stays active in your synapse, the longer you experience pain relief. The faster FAAH breaks it down, the shorter that relief window.

The variant: the FAAH C385A variant, the A allele, is carried by roughly 20 to 30% of the population. People with this variant have reduced FAAH activity, meaning anandamide lingers in their synapses longer. The result is naturally higher anandamide levels and a genetic predisposition toward lower pain sensitivity and more effective endogenous pain relief.

What this feels like: if you carry this variant, you typically experience pins and needles less intensely or recover from them more quickly than you might otherwise expect. The absence of this variant, however, means your natural endocannabinoid system is less robust, leaving you more vulnerable to pain amplification.